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Pregnancy complications associated with chronic fetal hypoxia have been linked to the 
development of adult cardiovascular disease in the offspring. Prenatal hypoxia has been 
shown to increase placental oxidative stress and impair placental function in a sex-specific 
manner, thereby affecting fetal development. As oxidative stress is central to placental 
dysfunction, we developed a placenta-targeted treatment strategy using the antioxidant 
MitoQ encapsulated into nanoparticles (nMitoQ) to reduce placental oxidative/nitrosative 
stress and improve placental function without direct drug exposure to the fetus in order 
to avoid off-target effects during development. We hypothesized that, in a rat model of 
prenatal hypoxia, nMitoQ prevents hypoxia-induced placental oxidative/nitrosative stress, 
promotes angiogenesis, improves placental morphology, and ultimately improves fetal 
oxygenation. Additionally, we  assessed whether there were sex differences in the 
effectiveness of nMitoQ treatment. Pregnant rats were intravenously injected with saline 
or nMitoQ (100 μl of 125 μM) on gestational day (GD) 15 and exposed to either normoxia 
(21% O2) or hypoxia (11% O2) from GD15 to 21. On GD21, placentae from both sexes 
were collected for detection of superoxide, nitrotyrosine, nitric oxide, CD31 (endothelial 
cell marker), and fetal blood spaces, Vegfa and Igf2 mRNA expression in the placental 
labyrinth zone. Prenatal hypoxia decreased male fetal weight, which was not changed by 
nMitoQ treatment; however, placental efficiency (fetal/placental weight ratio) decreased 
by hypoxia and was increased by nMitoQ in both males and females. nMitoQ treatment 
reduced the prenatal hypoxia-induced increase in placental superoxide levels in both male 
and female placentae but improved oxygenation in only female placentae. Nitrotyrosine 
levels were increased in hypoxic female placentae and were reduced by nMitoQ. Prenatal 
hypoxia reduced placental Vegfa and Igf2 expression in both sexes, while nMitoQ increased 
Vegfa and Igf2 expression only in hypoxic female placentae. In summary, our study 
suggests that nMitoQ treatment could be pursued as a potential preventative strategy 
against placental oxidative stress and programming of adult cardiovascular disease in 
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INTRODUCTION
Chronic fetal hypoxia, a common consequence of pregnancy 
complications (e.g., placental insufficiency), has been linked 
to the development of cardiovascular and metabolic diseases 
in the adult offspring. The placenta serves as feto-maternal 
interface for the exchange of nutrients and oxygen to the fetus. 
Placental insufficiency is often associated with placental oxidative 
and nitrosative stress (i.e., formation of reactive oxygen/nitrogen 
species; ROS/RNS). An imbalance in ROS/RNS levels caused 
by excessive generation of ROS and/or a fall in endogenous 
antioxidants such as superoxide dismutase (SOD) can lead to 
impaired placental development and altered placental function 
(reviewed in Al-Gubory et  al., 2010; Schoots et  al., 2018). 
One impact of excessive superoxide anions is the resultant 
scavenging of nitric oxide (NO) to produce RNS (e.g., 
peroxynitrite; Myatt and Cui, 2004); therefore, increased 
superoxide levels could reduce NO bioavailability and impair 
the important contribution of NO in feto-placental angiogenesis 
(Webster et  al., 2008).
Interestingly, the placental response to oxidative stress 
appears to be  different in placentae from males compared 
with females (reviewed in Rosenfeld, 2015). Human studies 
have shown that the placental oxidative stress response to 
adverse maternal environments (such as oxidative/nitrosative 
stress and reduced levels of antioxidants) in general appears 
to be more pronounced in male versus female placentae (Stark 
et  al., 2011; Sedlmeier et  al., 2014; Muralimanoharan et  al., 
2015; Evans and Myatt, 2017). In rodents, similar results 
were found, where adverse maternal environments (such as 
prenatal hypoxia) altered placental morphology, placental gene 
expression, and enzymes for epigenetic modifications (e.g., 
DNA methylation) in a sexually dimorphic manner (Mao 
et  al., 2010; Gabory et  al., 2012; Kim et  al., 2014; Thompson 
et  al., 2018). Therefore, examining sex-specific differences in 
the placental responses to adverse maternal environments or 
placental phenotypes as an outcome of the adverse environments 
is warranted.
As the placenta lacks both autonomic and cholinergic 
innervation, placental morphology and function are dependent 
on locally derived growth factors such as vascular endothelial 
growth factor A (VEGFA) and insulin-like growth factor 2 (IGF2; 
Reynolds and Redmer, 2001; Marzioni et  al., 2004). Expression 
of the pro-angiogenic factor VEGFA is regulated by the oxygen 
sensing family of transcription factors such as hypoxia-inducible 
factor-1 alpha (HIF-1α; Cuffe et  al., 2014). Placental hypoxia 
has been shown to impair feto-placental vascular development 
via VEGFA and HIF-1α (Kulandavelu et  al., 2013). 
Decreased IGF2 expression is also associated with intrauterine 
growth restriction (IUGR) and critical to placental morphology 
and nutrient transfer to the fetus (Coan et al., 2008). In addition, 
hypoxia and placental oxidative/nitrosative stress may cause 
mitochondrial dysfunction, DNA damage, or reduced expression 
of the antioxidant system, all of which can affect normal placental 
function and potentially reduce oxygen and nutrient delivery, 
thus impairing fetal development (Droge, 2002; Lappas et  al., 
2010; Thompson and Al-Hasan, 2012). Therefore, given that 
oxidative stress is a central mediator of placental dysfunction 
in fetal hypoxia, prenatal treatment of placental oxidative stress 
could potentially prevent the long-term effects of fetal hypoxia 
on adult offspring.
Mitochondria are a major source of cellular ROS (as reviewed 
in Holland et  al., 2017), and human placental tissues from 
complicated pregnancies were shown to have increased 
mitochondrial content, decreased respiratory chain complex 
expression, and impaired mitochondrial function (as reviewed 
in Mando et  al., 2014; Chiaratti et  al., 2015; McCarthy and 
Kenny, 2016). Therefore, our lab and others have been studying 
the potential use of the mitochondrial-targeted antioxidant 
MitoQ to target placental oxidative stress in complicated 
pregnancies (Phillips et al., 2017; Aljunaidy et al., 2018; Nuzzo 
et  al., 2018). MitoQ consists of a ubiquinone moiety linked 
to a positively charged lipophilic cation allowing for 
accumulation on the inner mitochondrial membrane, making 
it highly effective in preventing mitochondrial oxidative stress 
(Smith et  al., 1999; Ross et  al., 2005; Murphy and Smith, 
2007). Indeed, in a rat model of prenatal hypoxia, MitoQ 
treatment prevented the increase in mitochondrial stress markers 
in the placental labyrinth zone (Nuzzo et  al., 2018). Recently, 
we  have shown that MitoQ encapsulated into polymeric 
nanoparticles (nMitoQ) is a delivery approach to access the 
placental syncytium without crossing the placental basal 
membrane to reach the fetus (Aljunaidy et  al., 2017; Phillips 
et  al., 2017). With this treatment strategy, we  showed that 
maternal treatment with nMitoQ in a rat model of prenatal 
hypoxia prevented placental oxidative stress, increased fetal 
weight in female fetuses, improved neuronal development, and 
had sex-dependent beneficial effects on in vivo cardiovascular 
function in prenatally hypoxic adult offspring (Phillips et  al., 
2017; Aljunaidy et  al., 2018). Furthermore, nMitoQ treatment 
of human preeclamptic placental explants improved neuronal 
development in vitro (Scott et  al., 2018). However, the effect 
of nMitoQ treatment on placental morphology, the mechanisms 
via which reduced placental oxidative stress might improve 
placental function and fetal growth, and any potential sex 
differences are still under investigation.
offspring exposed to hypoxia in utero. However, sex differences need to be taken into 
account when developing therapeutic strategies to improve fetal development in 
complicated pregnancies, as nMitoQ treatment was more effective in placentae from 
females than males.
Keywords: placenta, hypoxia, MitoQ, nanoparticles, sex difference
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In the current study, we  aimed to further identify the effect 
of nMitoQ treatment on placental function and oxidative stress, 
and the sex-specific effects of the treatment, in a rat model 
of prenatal hypoxia. We  hypothesized that antioxidant nMitoQ 
treatment would decrease prenatal hypoxia-induced oxidative/
nitrosative stress along with increasing VEGFA expression, 
improving placental morphology, increasing IGF2 expression, 
and ultimately resulting in improved fetal growth. Moreover, 
since it has been shown that placentae from male and female 
fetuses respond to prenatal stress differently, we  hypothesized 
that there is a sex-specific divergence in the placental response 
to prenatal hypoxia-induced oxidative/nitrosative stress and the 
effectiveness of nMitoQ treatment.
MATERIALS AND METHODS
Ethics Approval
All procedures described were approved by the University of 
Alberta Animal Policy and Welfare Committee and were in 
accordance with the guidelines of the Canadian Council on 
Animal Care (AUP #242).
Preparation of Nanoparticle Encapsulated 
MitoQ (nMitoQ)
MitoQ loaded nanoparticles were synthesized as previously 
described (Phillips et al., 2017; Aljunaidy et al., 2018). Briefly, 
an amphiphilic copolymer of poly (γ-glutamic acid) and 
L-phenylalanine ethyl ester (γ-PGA-Phe) was synthesized 
as described previously (Kim et al., 2009). γ-PGA-Phe (10 mg/
ml) dissolved in dimethyl sulfoxide (DMSO) was added to 
an equivalent volume of sodium chloride (NaCl; 0.15  M), 
dialyzed against distilled water using a dialysis membrane, 
freeze-dried, and resuspended in phosphate-buffered Saline 
(PBS; 10  mg/ml). Nanoparticles were then measured by 
dynamic light scattering (Zetasizer Nano ZS, Malvern 
Instruments, UK) as diameter (180  nm), zeta potential 
(−20  mV), and polydispersity index (0.12). γ-PGA-Phe 
nanoparticles (10 mg/ml) were mixed with MitoQ (2 mg/ml) 
at equivalent volume in NaCl (0.2  M). Nanoparticles were 
isolated by centrifugation, washed, and resuspended in PBS 
(10  mg/ml). The amount of MitoQ (278  nm), 
which was adsorbed to nanoparticles, was evaluated by 
UV  absorption measurement, as previously described 
(Phillips et  al., 2017).
Prenatal Hypoxia Rat Model
Female Sprague-Dawley rats, 3  months of age (weighing 
250–275  g), were obtained from Charles River (Quebec, 
Canada) and housed in a temperature and light controlled 
room (10:14  h light/dark cycle) with ad libitum access to 
food and water. Females were housed with Sprague-Dawley 
males overnight, and pregnancy was confirmed the following 
morning by the presence of sperm in a vaginal smear, which 
was defined as gestational day (GD) 0 of pregnancy. On 
GD15, pregnant dams were randomly assigned into two 
groups that were exposed to either prenatal hypoxia (11% O2) 
by placing them in a Plexiglas hypoxic chamber from GD15 
to 21 or were housed at atmospheric oxygen (21% O2) as 
controls. Pregnant dams received an intravenous injection 
via the tail vein on GD15 with either saline or nMitoQ 
(100  μl of 125  μM nMitoQ). As nMitoQ is recycled and 
lasts up to 1 week in vivo, the nMitoQ treatment protocol 
consisted only of a single injection (Phillips et  al., 2017). 
The dose of nMitoQ was based on our previous studies 
(Phillips et  al., 2017; Aljunaidy et  al., 2018). As our study 
is focused on nMitoQ, as a single entity, we  have a saline 
control rather than a nanoparticle along group as the properties 
may be  different without the MitoQ and, ultimately, 
nanoparticles alone would never be used in practice. Previous 
studies have demonstrated that these nanoparticles are inert 
(Phillips et  al., 2017; Scott et  al., 2018). At the end of 
gestation, on GD21, rats were euthanized prior to parturition 
and fetal and placental weights were measured. Whole placentae 
(labyrinth and junctional zone) from male and female fetuses 
(two/sex/litter) were processed and embedded in either paraffin 
or optimal cutting temperature (OCT) compound for 
immunofluorescent and other staining procedures, as listed 
below. In other placentae (two/sex/litter), the placental labyrinth 
zones were isolated and snap frozen in liquid nitrogen for 
RNA and DNA methylation analysis.
Dihydroethidium Staining for Superoxide 
Production and Diaminofluorescein-FM 
(DAF-FM) for Nitric Oxide Levels
Placental cryostat sections (10  μm) were thawed, washed three 
times with Hank’s balanced salt solution (HBSS), and incubated 
with dihydroethidium (DHE) to measure superoxide levels 
(200 μM, Biotium, Burlington, Canada) or DAF-FM to measure 
nitric oxide levels (10  μM, Thermo Fisher Scientific, Eugene, 
OR, USA) in HBSS at 37°C for 30  min. Sections were washed 
with HBSS (3 × 2 min) and covered with a drop of 4′,6-diamidino-
2-phenylindole (DAPI) (Vector Laboratories). Sections were 
protected from light, and pictures were immediately taken to 
prevent photobleaching.
Immunofluorescent Nitrotyrosine  
Staining for Placental Peroxynitrite Levels 
and CD31 Staining to Assess  
Placental Labyrinth Feto-Placental 
Vascular Capillaries
Nitrotyrosine residues are the molecular footprint of 
peroxynitrite generation and can be  used as a marker of 
peroxynitrite (Webster et  al., 2008). CD31 was used as an 
endothelial marker (Newman, 1997) to assess placental 
vascularization. Placental cryostat sections (8 μm) were thawed, 
fixed in ice-cold acetone for 10  min, washed thrice in PBS, 
and non-specific binding was blocked using 2% bovine serum 
albumin (BSA) in PBS for 60  min. Sections were incubated 
overnight at 4°C with a primary antibody for nitrotyrosine 
(1:10; mouse-anti-tyrosine, NOVUS Biologicals, Oakville, 
ON, Canada) or CD31 (1:200 mouse-anti-CD31/PECAM-1, 
Ganguly et al. Sex-Specific Effects of nMitoQ Treatment
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NOVUS Biologicals) in 2% BSA/PBS. The next day, sections 
were washed thrice with PBS and incubated with secondary 
antibody [1:250  in 2% BSA/PBS; donkey anti-mouse IgG 
(H + L), AF488, Alexa, Invitrogen] for 1 h at room temperature. 
Sections were washed with PBS thrice, mounting medium 
containing DAPI was added (Vector Laboratories; Burlingame, 
CA, U.S.A) and slides were covered, protected from light 
and left to dry overnight. Images were taken the next day.
Immunofluorescent Staining for Placental 
HIF-1α Expression
Placental levels of the transcription factor hypoxia-inducible 
factor-1α (HIF-1α) were measured as a marker of hypoxia. 
Placental PFA-fixed sections (8  μm) were dewaxed in xylene 
and rehydrated in ethanol (100, 95 and 80%). Endogenous 
peroxidase activity was blocked using 10% H2O2 in distilled 
water for 10  min and incubated in sodium citrate buffer 
supplemented with 0.05% Tween 20 at 90°C for 20  min for 
antigen retrieval. Non-specific staining was blocked with 2% 
BSA/PBS for 60  min at room temperature and incubated 
overnight at 4°C with a primary antibody against HIF-1α 
(1:250; rabbit-anti-HIF1 alpha, NOVUS Biologicals, Oakville, 
ON, Canada) in 2% BSA/PBS. The next day, sections were 
washed twice with Tris buffered saline containing 0.05% Tween 
20 (TBS-T) and incubated with secondary antibody [1:250; 
goat-anti-rabbit IgG (H  +  L)-AF546, Invitrogen, Carlsbad, CA, 
USA] in TBS-T for 60 min at room temperature. After incubation 
with secondary antibody, sections were washed twice in TBS-T, 
once in distilled water and mounted using mounting medium 
containing DAPI (Vector Laboratories). Slides were protected 
from light and left to dry overnight. Images were taken the 
next day.
Immunofluorescent Staining for Placental 
and Fetal Tissue Oxygenation
In a separate group of dams, tissue oxygenation levels were 
assessed by intraperitoneal (i.p.) injection of either pimonidazole 
hydrochloride (60 mg/kg) (Hypoxyprobe™-1, Burlington, USA) 
or an equivalent volume of vehicle (saline) as a control on 
GD20. Six hours post injection, dams were euthanized, and 
placentae, fetal hearts, and fetal liver were collected and snap 
frozen. Pimonidazole levels in placental tissues and fetal cardiac 
and hepatic tissues from both sexes were assessed by 
immunostaining. Pimonidazole hydrochloride (also known as 
2-nitroimidazoles) distributes to all tissues but is activated by 
reduction in cells exposed to oxygen concentration less than 
14 micromolar, which is equivalent to a partial pressure 
pO2  =  10  mmHg at 37°C. The activated intermediate forms 
stable adducts with proteins containing thiol groups (i.e., reduced 
pimonidazole, the staining product). Placental cryosections 
(8  μm) were fixed in acetone (10  min) and washed in PBS 
thrice, and non-specific staining was blocked using 2% BSA/
PBS for 1  h. Sections were incubated overnight at 4°C with 
monoclonal anti-pimonidazole antibody (1:200; Hypoxyprobe™ 
Kit) in 2% BSA/PBS. The next day, sections were washed thrice 
in PBS and incubated with secondary antibody [1:250; donkey 
anti-mouse IgG (H  +  L), AF488, Alexa, Invitrogen] in 2% 
BSA/PBS for 60  min. Sections were washed with PBS three 
times and mounted using mounting medium containing DAPI 
(Vector Laboratories). Slides were protected from light and 
left to dry overnight. Images were taken the next day.
Morphological Analysis of Placenta
Using an established hematoxylin and eosin (H&E) staining 
protocol, placental PFA-fixed sections (8  μm) were dewaxed 
in histoclear, rehydrated, stained with filtered Harris’s hematoxylin 
for 3  min, washed with distilled water, and then put into 
filtered eosin for 30  s. The placental sections were washed in 
cold water, covered, and left to dry overnight.
Image Analysis
All images were taken on an Olympus IX81 fluorescence 
microscope with CellSens Dimensions software (Olympus, Japan) 
with TRITC at 532  nm (for DHE, HIF-1α staining) or FITC 
at 488  nm (for nitrotyrosine, DAF-FM and CD31 staining) 
wavelength, respectively. Three representative pictures of the 
placental labyrinth zone were randomly taken from each of 
the tissue section at 20× magnification. All pictures were 
corrected to the blank controls (i.e., samples without DHE, 
or samples incubated only with secondary antibodies) to remove 
background staining. Fluorescent images were analyzed using 
ImageJ 1.48 software (National Institutes of Health, Bethesda, 
MD, USA) to determine mean fluorescence intensity (MFI). 
MFI values from the DHE, nitrotyrosine, and pimonidazole 
staining were normalized to the nuclei counts per image. The 
average MFI of the three representative images per experimental 
group was taken.
For placental morphological analysis, images were taken 
with a digital camera mounted on a bright field microscope 
(EVOS XL Core Imaging System, Thermo Fisher Scientific, 
Canada) at a 2× magnification. For the other assessments, 
three randomly selected representative fields from each placenta 
were obtained at a magnification of 40×. Then, using ImageJ 
software, placental blood space area in each field of view was 
converted into black and remaining placental tissue into white 
for quantification. Total area of fetal blood space per field of 
view was calculated using ImageJ software, and the values were 
averaged per experimental group. Briefly, images were opened 
in ImageJ and converted into 16 bit binary images. Following 
which a threshold was set automatically by the program, which 
converted the placental blood space area into black and remaining 
placental tissue into white. Particle count of placental blood 
space was analyzed on ImageJ using the option of “analyze 
particles” in the software, which resulted in a surface area 
value for the black space, i.e., the placental blood space.
Real-Time RT-PCR for Placental Gene 
Expression of IGF and VEGFA
Total RNA was isolated from the placental labyrinth using 
RNeasy plus Mini Kit (QIAGEN Inc., Ontario, Canada). 
Ganguly et al. Sex-Specific Effects of nMitoQ Treatment
Frontiers in Physiology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 562
Total RNA was reverse transcribed to cDNA using the High 
Capacity cDNA Reverse Transcription Kit (AB Applied 
Biosystems, Warrington, UK) according to the manufacturer’s 
instructions. Using gene-specific primers for Igf2, Igf2P0, 
Igf1r, Igf2r, and Vegfa, quantitative real time RT-PCR (qPCR) 
was performed using iQ™ SYBR Green Supermix (Bio-Rad, 
Hercules, CA, USA; see Table 1 for primers). Briefly, thermal 
cycling was initiated by a 5  min. Denaturation at 95°C, 
followed by 40  cycles of 95°C for 30 s, annealing at 60°C 
for 15  s, and 72°C for 30 s. Samples without reverse 
transcriptase (RT) using the same PCR primers were done 
as a control for the presence of genomic DNA. The 
gene expression levels in each sample (absolute quantification) 
were calculated from the standard curve (for each 
primer set) and normalized to rat Cyclophilin A 
(PPIA) expression.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 
7.04 software (GraphPad Software, U.S.A.). All data are 
expressed as mean  ±  SEM. All data were analyzed using a 
two-way ANOVA, with hypoxia and nMitoQ treatment as 
the two independent factors, followed by Sidak’s multiple 
comparison post hoc tests. A value of p  <  0.05 was 
considered significant.
RESULTS
Offspring and Placental Characteristics
In male fetuses, prenatal hypoxia decreased fetal weight and 
abdominal girth without affecting placental weight (Table 2). 
nMitoQ treatment increased male abdominal girth in the 
prenatal hypoxia exposed group, while no effects of nMitoQ 
treatment were observed on fetal or placental weights in males 
(Table 2). Prenatal hypoxia reduced placental efficiency and 
expressed as ratio of fetal weight/placental weight in male 
fetuses, which was not significantly improved by nMitoQ 
treatment; however, placental efficiency in the hypoxia/nMitoQ 
group was no longer significantly different than normoxia/
saline controls (Table 2), suggesting an effect of nMitoQ 
treatment. Crown-to-rump length was similar between all 
experimental groups in male fetuses (Table 2).
In female fetuses, prenatal hypoxia had no effect on fetal 
weight or abdominal girth but increased placental weight, which 
was significantly reduced by nMitoQ treatment (Table 3). 
nMitoQ treatment had no effect on female fetal weight or 
abdominal girth (Table 3). Prenatal hypoxia reduced placental 
efficiency and expressed as ratio of fetal weight/placental weight 
in female fetuses, which was not significantly improved by 
nMitoQ treatment; however, placental efficiency in the hypoxia/
nMitoQ group was no longer significantly different normoxia/
saline controls (Table 3). Crown-to-rump length was similar 
between all experimental groups in female fetuses (Table 3).
nMitoQ Treatment Improved  
Placental Oxidative/Nitrosative  
Stress in Female Offspring
Superoxide and peroxynitrite levels were assessed as markers 
of oxidative/nitrosative stress. In male offspring, superoxide 
levels were significantly increased in offspring exposed to 
prenatal hypoxia compared to normoxic control offspring 
(Figure 1A). nMitoQ treatment significantly decreased placental 
superoxide generation in prenatally hypoxic male offspring and 
had no effect in the control group (Figure 1A). Nitrotyrosine 
levels (Figure 1B) or nitric oxide levels (Figure 1C) were not 
TABLE 2 | Fetal and placental characteristics of male offspring.
Variables Normoxia p-Hypoxia Main effect
Saline nMitoQ Saline nMitoQ p-Hypoxia nMitoQ Interaction
Fetal weight (g) 5.81 ± 0.24 5.6 ± 0.15 5.21 ± 0.19 5.13 ± 0.26 * – –
Placental weight (g) 0.61 ± 0.04 0.58 ± 0.03 0.61 ± 0.02 0.62 ± 0.03 – – –
Fetal weight/placental 
weight
9.05 ± 0.39 9.76 ± 0.50 7.96 ± 0.78 8.69 ± 0.56 – – –
Abdominal girth (cm) 3.87 ± 0.08 3.72 ± 0.05 3.32 ± 0.13 3.82 ± 0.13† * – **
Crown-rump length (cm) 4.78 ± 0.09 4.92 ± 0.12 4.47 ± 0.18 4.82 ± 0.13 – – –
Body weight, placental weight, placental efficiency (body weight/placental weight), abdominal girth, and crown-rump length from male fetuses collected on GD21. Data are 
represented as mean ± SEM. All groups were compared using a two-way ANOVA followed by Sidak’s post hoc test.
*p < 0.05 overall group effect of prenatal hypoxia.
**p < 0.01 interaction between prenatal hypoxia and nMitoQ treatment.
†p < 0.05 versus corresponding hypoxia-saline group. Exact p-value is p = 0.006.
TABLE 1 | Quantitative real-time PCR primers.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
Igf2 TGT CTA CCT CTC AGG CCG 
TAC TT
TCC AGG TGT CGA ATT TGA 
AGA A
Igf2P0 GAT CAT CGT CCA GGC AAT TT GTT GCG TAG TTC CCG AAG TT
Igf1r AAG GAT GGC GTC TTC ACC A GAG TGG CGA TCT CCC AGA G
Igf2r CTG CAG GCG GGA AAG TTC CAC TCT TAT CCA CAG 
CAC
Vegfa GTG CAC TGG ACC CTG GCT TT TTC ACC ACT TCA TGG GCT 
TTC TG
Ppia AGC ATA CAG GTC CTG GCA TC TTC ACC TTC CCA AAG ACC AC
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affected by prenatal hypoxia or nMitoQ treatment in placentae 
from male offspring.
In female offspring, superoxide levels significantly increased 
in offspring exposed to prenatal hypoxia were significantly 
decreased by nMitoQ treatment in prenatally hypoxic offspring 
and had no effect in the control group (Figure 1D). Nitrotyrosine 
levels tended to be  increased in the placentae of prenatally 
hypoxic female offspring (Figure 1E). Moreover, there was a 
significant interaction between nMitoQ treatment and prenatal 
hypoxia exposure in which nMitoQ treatment decreased 
A B C
D E F
FIGURE 1 | Effects of nMitoQ treatment on placental superoxide, peroxynitrite, and NO levels in normoxic and hypoxic placentae of both male and female 
offspring. Normoxic and hypoxic dams were treated with nMitoQ or saline, and superoxide levels were assessed by DHE staining in placentae from male (A) and 
female (D) fetuses; peroxynitrite levels were detected by staining for nitrotyrosine (the footprint of peroxynitrite production) in placentae from male (B) and female (E) 
fetuses, and NO levels were assessed by DAF-FM staining in placentae from male (C) and female (F) fetuses on GD21. Data are represented as mean ± SEM. a.u.: 
arbitrary units. All groups were compared using a two-way ANOVA followed by Sidak’s post hoc test (n = 6–7/group). *p < 0.05, **p < 0.01 group effect of prenatal 
hypoxia or nMitoQ treatment; ##p < 0.01, ###p < 0.001 compared to normoxia-saline; ††p < 0.01, †††p < 0.001 compared to hypoxia-saline group.
TABLE 3 | Fetal and placental characteristics of female offspring.
Variables Normoxia p-Hypoxia Main effect
Saline nMitoQ Saline nMitoQ p-Hypoxia nMitoQ Interaction
Fetal weight (g) 5.16 ± 0.29 5.81 ± 0.14 5.17 ± 0.16 5.26 ± 0.09 – – –
Placental weight (g) 0.56 ± 0.01 0.59 ± 0.01 0.62 ± 0.02 0.56 ± 0.01† – – *
Fetal weight/placental weight 9.06 ± 0.54 9.7 ± 0.31 7.7 ± 0.62 8.72 ± 0.44 – – –
Abdominal girth (cm) 3.67 ± 0.11 3.77 ± 0.13 3.38 ± 0.13 3.7 ± 0.12 – – –
Crown-rump length (cm) 4.7 ± 0.15 4.8 ± 0.10 4.56 ± 0.14 4.63 ± 0.07 – – –
Body weight, placental weight, placental efficiency (body weight/placental weight), abdominal girth, and crown-rump length from female fetuses collected on GD21. Data are 
represented as mean ± SEM. All groups were compared using a two-way ANOVA followed by Sidak’s post hoc test.
*p < 0.05 overall group effect of prenatal hypoxia.
†p < 0.05 versus corresponding hypoxia-saline group. Exact p-value is p = 0.04
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nitrotyrosine levels in placentae of only female hypoxic offspring 
(Figure 1E). However, hypoxia significantly increased nitric 
oxide levels in placentae from female offspring, but there was 
no effect of nMitoQ treatment (Figure 1F).
nMitoQ Treatment Decreased Markers  
of Placental and Fetal Hypoxia in  
Female Offspring
We next assessed HIF1-α protein levels as a marker for 
tissue hypoxia and confirmed placental oxygenation levels 
by pimonidazole staining. HIF1-α expression was significantly 
increased in prenatal hypoxia-exposed placentas from male 
offspring, which was not reduced by nMitoQ treatment 
(Figure  2A). There was a significant interaction between 
nMitoQ treatment and prenatal hypoxia in male placentae, 
whereby nMitoQ increased HIF1-α expression in placentae 
from normoxic male offspring (Figure 2A). Placental 
oxygenation was decreased (as shown by increased 
pimonidazole staining) in placentae of male offspring, which 
was unaffected by nMitoQ treatment (Figure 2B). Prenatal 
hypoxia decreased oxygenation in fetal hearts of only male 
offspring, while nMitoQ increased oxygenation in only 
prenatally hypoxic hearts of male offspring (Figure 2C). 
Hepatic oxygenation was reduced in livers of male offspring, 
but nMitoQ treatment had no effect (Figure 2D).
Prenatal hypoxia significantly increased placental HIF1-α 
expression in female offspring (Figure 2E). nMitoQ treatment 
decreased HIF1-α expression in placentae from female offspring 
exposed to prenatal hypoxia (Figure 2E). There was a significant 
interaction between nMitoQ treatment and prenatal hypoxia 
in female placentae, whereby nMitoQ increased HIF1-α 
expression in placentae from normoxic female offspring 
(Figure  2E). Placental oxygenation was also decreased (as 
shown by increased pimonidazole staining) in placentae of 
female offspring exposed to prenatal hypoxia (Figure 2F). 
nMitoQ treatment significantly increased oxygenation in 
placenta of only female offspring exposed to prenatal hypoxia 
(Figure 2F). There was no effect of prenatal hypoxia on 
oxygenation in fetal hearts of female offspring, while nMitoQ 
increased oxygenation in hearts of female offspring 
(Figure  2G). Hepatic oxygenation was reduced in livers of 
prenatally hypoxic female offspring, and nMitoQ treatment 
increased oxygenation in livers of only female offspring 
exposed to prenatal hypoxia (Figure 2H).
nMitoQ Treatment Increased Angiogenesis 
and Vascularization in Placentae of  
Female Offspring
Placental hypoxia is commonly associated with altered expression 
of the placental pro-angiogenic peptide vascular endothelial 
growth factor (VEGF; Lyall et  al., 1997; Roh et  al., 2005). In 
male offspring, prenatal hypoxia decreased placental Vegf mRNA 
expression, which was not altered by nMitoQ 
treatment (Figure  3A). Prenatal hypoxia also reduced 
A B C D
E F G H
FIGURE 2 | Effects of nMitoQ treatment on placental and fetal hypoxia. Expression of HIF1-α protein, a marker for tissue hypoxia in placentae obtained from male 
(A) and female (E) fetuses on GD21. Oxygenation levels as assessed by pimonidazole staining in the placentae of male (B) and female (F), the cardiac tissues of 
male (C) and female (G) and hepatic tissues of male (D) and female (H) fetuses on GD21. Data are represented as mean ± SEM. a.u.: arbitrary units. All groups 
were compared using a two-way ANOVA followed by Sidak’s post hoc test (n = 5–6/group). *p < 0.05, **p < 0.01 group effect of prenatal hypoxia and nMitoQ 
treatment; #p < 0.05, ##p < 0.01 compared to normoxia-saline; †p < 0.05, ††p < 0.01 compared to hypoxia-saline group.
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CD31-positive area of staining (i.e., the fetal capillaries; 
Figures  3B,C). There was a significant interaction between 
nMitoQ treatment and prenatal hypoxia in male placentae, 
whereby nMitoQ reduced both Vegf and CD31 staining in 
placentae from normoxic male offspring (Figures 3A,B).
In female offspring, prenatal hypoxia decreased placental 
Vegf mRNA expression, which was increased by nMitoQ 
treatment in placentae from prenatally hypoxic female offspring 
(Figure 3D). CD31-positive area of staining (i.e., the fetal 
capillaries) was reduced by prenatal hypoxia in placentae from 
female offspring (Figures 3E,F). Similar to the Vegf expression 
pattern, there was a significant interaction between nMitoQ 
treatment and prenatal hypoxia in female placentae, whereby 
nMitoQ increased CD31 staining only in the placentae from 
prenatal hypoxic female offspring (Figure 3E).
Sufficient fetal blood space in the placental labyrinth 
zone is essential for oxygen and nutrient exchange between 
the maternal and fetal circulations (Burton and Fowden, 
2015). We  found that prenatal hypoxia reduced fetal and 
maternal blood space area in placentae from only male 
offspring (Figures  4A,B). nMitoQ did not change fetal 
and  maternal blood space area in placentae from males 
(Figure 4A); however, in female offspring, nMitoQ treatment 
increased fetal blood space area in placentae exposed to 
prenatal hypoxia  (Figures 4C,D).
nMitoQ Treatment Increased Placental 
Igf2 in Female Offspring
IGF2 plays an important role in placental development 
(Fowden et  al., 2006), and total placental Igf2 and Igf2 
expressed only in the placental labyrinth region (i.e., Igf2P0) 
were shown to regulate the nutrient exchange characteristics 
of the placenta (Sibley et  al., 2004). In male offspring, 
prenatal hypoxia decreased total Igf2 and placental-specific 
Igf2 expression, which was not affected by nMitoQ treatment 
(Figures 5A,B). In placentae from female offspring, total 
Igf2 and placental-specific Igf2 expression were significantly 
decreased by prenatal hypoxia (Figures 5C,D). Moreover, 
nMitoQ treatment increased Igf2 expression in the prenatal 
hypoxia-exposed female placentae only (Figure 5C). 
Expression levels of the IGF2 receptors, Igf1r and Igf2r, 
were decreased in placentae of both prenatally hypoxic male 
and female offspring but were not affected by nMitoQ 
treatment (Figures 6A–D).
A B C
D E F
FIGURE 3 | Effects of nMitoQ treatment on markers of angiogenesis and vascularization in prenatally hypoxic placentae of both male female offspring. 
Proangiogenic factor Vegfa mRNA levels were assessed by qPCR in placental tissue obtained from male (A) and female (D) fetuses on GD21. Feto-placental 
vascular capillaries as assessed by CD31 staining in placentae obtained from male (B) and female (E) fetuses. Representative images of CD31 stained placental 
labyrinth sections in placentae of male (C) and female offspring (F). Data are represented as mean ± SEM. a.u.: arbitrary units. All groups were compared using a 
two-way ANOVA followed by Sidak’s post hoc test (n = 5–9/group). *p < 0.05, **p < 0.01 group effect of prenatal hypoxia and nMitoQ treatment; ##p < 0.01 
compared to normoxia-saline; †p < 0.05 compared to hypoxia-saline group.
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DISCUSSION
In the current study, we  hypothesized the sex-specific effects 
of preventing placental oxidative/nitrosative stress using nMitoQ, 
with a specific focus on placental morphology. This is of particular 
interest because oxidative stress in the placenta has been implicated 
to play a key role in the etiology of pregnancy complications 
such as fetal hypoxia and IUGR. Hence, our study was designed 
to elucidate possible mechanism(s) in the placenta that may 
account for differences in placental and fetal oxygenation and 
weights following a hypoxic insult and the sexually dimorphic 
effects of nMitoQ treatment. We  showed that a reduction in 
A B
C D
FIGURE 4 | Effects of nMitoQ treatment on fetal blood space area in prenatally hypoxic placentae of both male and female offspring. Fetal blood space area 
per field of view in labyrinth zones of placenta obtained from male (A) and female (C) fetuses on GD21. Representative images of H&E stained placental 
labyrinth sections in placentae of males (B) and females (D). Data are represented as mean ± SEM. All groups were compared using a two-way ANOVA 
followed by Sidak’s post hoc test (n = 5/group). *p < 0.05 group effect of prenatal hypoxia, #p < 0.05 compared to normoxia-saline, †p < 0.05 compared to 
hypoxia-saline group.
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placental ROS/RNS by nMitoQ treatment improved oxygenation, 
increased expression of VEGFA (known to affect placental 
morphology), and increased expression of Igf2. Moreover, nMitoQ 
treatment was more effective in placentae of female offspring 
than males. Our data demonstrated that the placental response 
to prenatal hypoxia is different in males versus females and 
that within the same dams, the response of the placentae to 
nMitoQ treatment is sexually dimorphic, resulting in sex differences 
in the effect of nMitoQ treatment on placental oxidative stress, 
vascularization, and placental and fetal growth.
Given that oxidative stress is a central mediator of placental 
dysfunction, we  and others have studied the use of an 
antioxidant to protect the placenta against oxidative stress 
(Phillips et al., 2017; Nuzzo et al., 2018). Recently, the antioxidant 
benefits of MitoQ treatment on placental adaptations from hypoxic 
pregnancies were extensively studied in male offspring (Nuzzo 
et  al., 2018). Nuzzo et  al. showed that MitoQ given daily to 
hypoxic pregnant dams in drinking water from GD6 to GD20 
restored placental efficiency to control levels, increased absolute 
placental volume, fetal capillary surface area in placental labyrinth 
zone, and maternal blood spaces related to placentae from normoxic 
pregnancies (Nuzzo et  al., 2018). The placental morphological 
adaptations (i.e., increased placental weight, increased fetal capillary 
surface area) to early-onset hypoxia (GD6–GD20) demonstrated 
in males were contrary to the placental morphological phenotype 
(i.e., unchanged placental weight and reduced fetal capillary area) 
A B
C D
FIGURE 5 | Effects of nMitoQ on placental Igf2 mRNA expression in prenatally hypoxic placentae of both male and female offspring. Growth factor Igf2 (A,C) and 
Igf2p0 (B,D) mRNA levels as assessed by qPCR in placentae obtained from male (A,B) and female (C,D) fetuses on GD21. Data are represented as mean ± SEM. 
All groups were compared using a two-way ANOVA followed by Sidak’s post hoc test (n = 5–9/group). *p < 0.05, **p < 0.01 group effect of prenatal hypoxia; 
##p < 0.01 compared to normoxia-saline; ††p < 0.01 compared to hypoxia-saline group.
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observed in our model of late-onset hypoxia (GD15  –GD21) in 
male offspring. Thus, diverse prenatal hypoxia insults can affect 
pregnancies differently, which need to be taken into consideration 
for clinical translation of findings. In our study, using MitoQ 
encapsulated in nanoparticles (nMitoQ) to target the placenta 
in order to limit direct drug exposure to the fetus and avoid 
potential off-target effects during fetal development, we  also 
observed beneficial effects; however, nMitoQ treatment was more 
effective in placentae of female offspring than males.
In our model of prenatal hypoxia, placental efficiency (fetal 
weight/placental weight) was reduced in both male and female 
fetuses, which was partially improved by nMitoQ treatment 
in both males and females. Interestingly, fetal weight was 
reduced by prenatal hypoxia only in males but not females, 
indicating that males may be more severely affected by prenatal 
hypoxia than females, as has been suggested in other studies 
(Stark et  al., 2011; Muralimanoharan et  al., 2015; Evans and 
Myatt, 2017). This reduction in fetal weight suggests insufficient 
oxygen and nutrient delivery to the fetus in the hypoxia exposed 
dams. Interestingly, in females, prenatal hypoxia increased 
placental weight, which was prevented by nMitoQ treatment. 
This may suggest that females, in compensation for the hypoxic 
environment, increased placental growth in order to increase 
oxygen and nutrient supply to the fetus and prevent growth 
restriction, which was indeed successful, as fetal weights in 
the females were not affected by prenatal hypoxia.
We showed that prenatal hypoxia increased oxidative stress 
(superoxide generation in male and female placentae), as 
A B
C D
FIGURE 6 | Effects of nMitoQ treatment on Igf1r and Igf2r mRNA expression in prenatally hypoxic placentae of both male and female offspring. Receptors for IGF2, 
Igf1r (A,C) and Igf2r (B,D) mRNA levels were assessed by qPCR in the labyrinth zones of placentae taken from male (A,B) and female (C,D) fetuses on GD21.  
Data are represented as mean ± SEM. All groups were compared using a two-way ANOVA followed by Sidak’s post hoc test (n = 4/group). *p < 0.05, **p < 0.01 
group effect of prenatal hypoxia or nMitoQ treatment; ##p < 0.01 compared to normoxia-saline.
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demonstrated previously (Richter et  al., 2012; Aljunaidy et  al., 
2018; Nuzzo et  al., 2018), and nitrosative stress (peroxynitrite 
formation in only female placentae). Oxidative and nitrosative 
stresses can inhibit normal placental development in various 
ways (e.g., inhibit mitochondrial electron transport and oxidation 
of DNA) and potentially reduce oxygen and nutrient delivery, 
thus impairing fetal development (Droge, 2002; Thompson and 
Al-Hasan, 2012). The nMitoQ treatment was therefore specifically 
designed to prevent oxidative stress in the placenta, and indeed, 
nMitoQ treatment significantly decreased placental superoxide 
and peroxynitrite levels. This supports our hypothesis that using 
MitoQ loaded nanoparticles as a targeted delivery system to 
the placenta is an effective treatment against the generation 
of reactive oxygen/nitrogen species in the placenta in 
compromised pregnancies. Interestingly, in female offspring, 
we  observed that the increased superoxide/peroxynitrite levels 
by prenatal hypoxia coincided with increased NO levels. Under 
normal pregnancy conditions, NO bioavailability promotes 
feto-placental vasodilation and induces angiogenesis (Cooke, 
2003; Kwon et al., 2004). The placental circulation lacks autonomic 
and cholinergic innervation, thus feto-placental angiogenesis 
and placental vascular resistance and function are dependent 
on locally derived vasoactive factors (e.g., NO) and growth 
factors (e.g., VEGF and IGF2; Pacher et al., 2007; Krause et al., 
2011; Kulandavelu et  al., 2013). In the human placenta, all 
nitric oxide synthase (NOS) isoforms are expressed but 
differentially within the tissues. Endothelial NOS (eNOS) isoform 
is predominantly expressed in syncytiotrophoblasts and 
endothelial cells (reviewed by Aban et al., 2018), while neuronal 
NOS (nNOS) and inducible NOS (iNOS) isoforms are expressed 
in the placental smooth muscle cells, syncytiotrophoblasts, 
extravillous trophoblasts, and hofbauer cells of the villous stroma 
(reviewed by Krause et  al., 2011). Moreover, studies have 
correlated increased placental vascular resistance and placental 
dysfunction to decreased eNOS and increased inducible NOS 
(iNOS) isoform expression, leading to increased nitrosative 
stress (Casanello and Sobrevia, 2002; Giannubilo et  al., 2008). 
Interestingly, IUGR has been associated with higher levels of 
placental NO, together with increased nitrosative stress and 
inadequate feto-placental vascularization (Lyall et  al., 1996; 
Tikvica et  al., 2008; Myatt, 2010). Therefore, the increased NO 
levels in female placentae may be  an immediate adaptive 
mechanism to prenatal hypoxia, which may be  associated with 
placental vascular dysfunction. Although we  have not assessed 
NOS isoforms and the contribution of various cell types to 
the increased placental NO levels in females, the above studies 
may suggest that increased iNOS expression and/or activity 
could be a potential source for increased placental NO observed 
in our model of prenatal hypoxia.
We found that prenatal hypoxia decreased placental and 
fetal oxygenation (in males and females), which coincided with 
an increase in HIF-1α levels in both sexes. Systemic and 
placental responses to hypoxia are orchestrated by hypoxia-
inducible factors (such as HIF-1α), and being a marker of 
hypoxia, this finding is in accordance with the reduced placental 
oxygenation we observed. Notably, in only the female prenatally 
hypoxic placentae, nMitoQ treatment effectively improved 
placental oxygenation. Moreover, the effect of prenatal hypoxia 
on oxygenation was more pronounced in the female fetal liver 
than the fetal heart, as previously reported by our laboratory, 
but only in male offspring (Rueda-Clausen et  al., 2011). 
Interestingly, nMitoQ treatment improved oxygenation in the 
hearts of both male and female fetuses, but in the liver, only 
female fetuses showed improved oxygenation with nMitoQ. 
Moreover, placental HIF-1α was only decreased by nMitoQ 
in the female placentae. This may explain why the female 
fetuses did not show any signs of significant growth restriction, 
as nMitoQ effectively decreased oxidative stress and HIF-1α 
and reduced placental weight in the female placentae. The 
underlying mechanisms for reduced effectiveness of nMitoQ 
treatment in males are not fully understood and remain to 
be  further studied. A possible explanation might be  that males 
show greater growth rate in utero (Parker et al., 1984); therefore, 
the higher oxygen and nutrient demand by the male fetus 
may predispose them to a greater risk of adverse developmental 
outcomes following the oxygen deprivation (Ozaki et al., 2001).
Oxidative stress is known to contribute to abnormal placental 
growth, function, and angiogenesis (Burton et  al., 2009). As 
mentioned above, the placenta lacks autonomic innervation, and 
locally derived NO and growth factors such as the pro-angiogenic 
factor VEGF play essential roles in placental vascular development 
and function (Kulandavelu et  al., 2013). HIF-1α (in hypoxic 
conditions) has been shown to increase VEGFA expression, while 
a reduction in VEGF has been observed in placentae from 
complicated pregnancies such as preeclampsia (Andraweera et al., 
2012; Abe et  al., 2013). Therefore, placental angiogenesis is 
dependent on locally derived VEGFA. Our study showed that 
prenatal hypoxia decreased Vegfa mRNA expression and the 
area of fetal blood capillaries (measured by endothelial cell 
marker CD31) in placentae of both male and female offspring, 
suggesting decreased angiogenesis and vascularization. The 
decreased Vegfa mRNA expression could be  due to decreased 
binding of HIF-1α to the hypoxia responsive element (HRE) 
on the Vegfa gene, which was previously shown by Myatt et  al. 
to decrease Vegfa expression in preeclamptic placentae with 
increased ROS (Muralimanoharan et  al., 2012). Interestingly, 
nMitoQ treatment only improved Vegfa mRNA expression, the 
area of fetal blood capillaries, and the placental blood space in 
the female placentae but not in the male placentae. The specific 
mechanisms remain to be  investigated, but it may be  speculated 
that this could be  mediated in part by increased placental NO 
levels present in the prenatally hypoxic placentae, which were 
not affected by nMitoQ treatment and could increase VEGFA. 
However, the effects of NO on VEGFA expression vary for 
different tissues and cell types (Abe et  al., 2013); therefore, NO 
mediated VEGFA expression within the placenta may be  highly 
dependent on the different cell types. Our data are in accordance 
with the previous studies, where MitoQ (not bound to 
nanoparticles) was shown to increase maternal blood space 
surface area in the placenta in males only (Nuzzo et  al., 2018). 
Taken together, our data could suggest that reduction of superoxide 
by nMitoQ could lead to enhanced angiogenesis via increased 
Vegfa expression and fetal capillary area and blood space in 
placentae of female offspring.
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Another important growth factor for placental 
morphogenesis is IGF2 (Sferruzzi-Perri et  al., 2017). In 
humans, decreased placental IGF2 has been associated with 
IUGR (Diplas et  al., 2009). In mice, genetic knockouts of 
Igf2 showed impaired placental development and fetal growth 
with reduced placental transfer of nutrients to the fetus 
(Constancia et  al., 2005; Coan et  al., 2008). We  observed 
that prenatal hypoxia decreased expression of Igf2 and Igf2P0 
in the labyrinth zone of both male and female offspring. 
This is in line with the previous studies showing that maternal 
exposure to hypoxia has direct effects on total Igf2 expression 
in the placenta: maternal exposure to 10–12% oxygen during 
late gestation decreased Igf2 expression, which affected the 
labyrinth layer morphology and decreased maternal blood 
space (Cuffe et  al., 2014; Higgins et  al., 2016). Hence, the 
reduction in placental Igf2 expression could also explain the 
decreased fetal blood spaces by prenatal hypoxia that 
we observed. The expression of Igf2 is regulated by methylation 
of the Igf2 gene at the imprinting control region (ICR) and 
the differentially methylated region 2 (DMR2). Recent studies 
suggest that a suboptimal intrauterine environment leads to 
epigenetic changes in the Igf2 gene and associated Igf2 
expression in growth restricted offspring of rats exposed to 
bilateral uterine artery ligation (Gonzalez-Rodriguez et  al., 
2016). Interestingly, hypoxic stress responses in general appear 
to be  driven by epigenetic changes (Cerda and Weitzman, 
1997). For example, prenatal hypoxia increased placental ROS 
and DNA methylation enzymes (Gheorghe et  al., 2007). 
Therefore, we  speculate that the methylation status at ICR 
and DMR2 may differ in a sex-specific manner, and changes 
in DNA methylation could account for the altered Igf2 
expression, which will be the focus for our future investigations.
It is well known that the placenta functions and adapts to 
an adverse intrauterine environment in a sex-specific manner 
(reviewed by Clifton, 2010). Furthermore, generation of oxidative 
stress differs in both male and female fetuses and placentae 
under conditions of adverse prenatal stress (Chaudhari et  al., 
2014). Our current study further demonstrates a dichotomous 
sex-specific and nMitoQ-specific effect on the placenta and 
ultimately fetal development. Overall, our data suggested that 
nMitoQ treatment decreased oxidative/nitrosative stress, 
improved oxygenation, was effective in bringing Vegfa and 
Igf2 expression back to control levels, and increased fetal blood 
space only in female placentae, thereby showing that nMitoQ 
treatment may protect offspring from the detrimental effects 
of a hypoxic insult in a sexually dimorphic manner with 
increased effectiveness in females. Of note, our data showed 
that nMitoQ treatment also affected the placenta in the control 
groups. For example, in normoxic controls, nMitoQ treatment 
increased HIF-1α expression in both male and female placentae 
and reduced CD31 area in the male offspring. Previous studies 
have demonstrated that maternal antioxidant supplementation 
with ascorbic acid in normal pregnancies was associated with 
vascular dysfunction and weight gain (Richter et  al., 2012). 
Therefore, continuing these studies we  need to keep in mind 
that this treatment is specifically designed to treat pregnancies 
complicated by fetal hypoxia and be  aware that there might 
be  detrimental effects of maternal antioxidant intervention 
during normal pregnancy.
To conclude, we demonstrated that nMitoQ treatment reduced 
placental nitrosative stress and improved oxygenation and 
placental morphology via increased VEGFA and IGF2 expression 
in a sex-specific manner, showing more effectiveness in placentae 
from female offspring. Moreover, our study shows that male 
fetuses appear to be  more susceptible to an adverse in utero 
environment. Although the exact mechanism(s) remain to 
be further investigated, a higher pro-oxidant state with reduced 
antioxidant capacity in the male placentae may explain the 
increased susceptibility of the male offspring under adverse 
conditions. In addition, our current study illustrates that the 
placenta is a contributing factor in the sexual dimorphism 
that has been observed in fetal programming. Thus, sex differences 
will need to be  taken into account when developing placental-
targeted therapeutic interventions to prevent fetal hypoxia and 
ultimately optimize fetal development in complicated pregnancies.
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